Myriad Genetics, Inc. (MYGN)
| Market Cap | 434.81M -52.3% |
| Revenue (ttm) | 824.50M -1.6% |
| Net Income | -365.90M |
| EPS | -3.95 |
| Shares Out | 93.51M |
| PE Ratio | n/a |
| Forward PE | 96.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,565 |
| Open | 4.740 |
| Previous Close | 4.770 |
| Day's Range | 4.560 - 4.740 |
| 52-Week Range | 3.760 - 8.590 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 7.64 (+64.3%) |
| Earnings Date | May 5, 2026 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion... [Read more]
Financial Performance
In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MYGN stock is "Buy." The 12-month stock price target is $7.64, which is an increase of 64.30% from the latest price.
News
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million...
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical val...
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings c...
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CE...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will particip...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expect...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
Faster initial remission and response, persistent benefit over six months Faster initial remission and response, persistent benefit over six months
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings confe...
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recomme...
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
Data Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowe...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI te...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI...
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published...
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta...
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been pro...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than ...
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
Myriad Genetics announced financial results for its second quarter ended June 30, 2025, updated full-year 2025 financial guidance on business performance.
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators Two Molecular Residual Disease (MRD) studies highlighting clini...
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...